Bronchoconstriction

Researchers are studying biomarkers from 129Xe gas exchange MRI to understand how they change with different medical interventions. The study focuses on interactions between 129Xe and red blood cells in the lungs. Participants include healthy volunteers and patients with conditions like interstitial lung disease, pulmonary hypertension, acute or chronic pulmonary embolism, anemia, polycythemia, and dyspnea. The study uses hyperpolarized xenon gas inhaled in multiple doses followed by breath holds, alongside oxygen administration. Participants are grouped by treatment: those undergoing transfusion or phlebotomy, patients receiving oxygen for lung-related conditions or healthy volunteers, and those recently diagnosed with acute or chronic pulmonary embolism. Treatments and responses are monitored at baseline and various follow-up points. Participants will undergo MRI scans to measure red blood cell transfer, chemical shifts after oxygen delivery, and changes in red blood cell signal oscillations before and after treatment. The study includes visits up to 3–6 months after interventions to track changes. Researchers also monitor safety and participant adherence throughout the study, which lasts until mid-2028.

The 3TR-ABC study is a large, multicenter observational research project that follows patients with severe asthma starting biological therapy and continues for three years. It aims to understand how patients respond to these treatments by examining clinical features, biomarkers, and immune system mechanisms. The study also includes healthy individuals and patients with mild to moderate controlled asthma as comparison groups to better understand differences in disease and treatment response. Participants with severe asthma who are beginning biological treatments will be assessed at the start of the study and then followed at set intervals: 4 weeks, 16 weeks, 52 weeks, 2 years, and 3 years. The study collects various biological samples for advanced analysis and uses innovative methods such as exhaled breath analysis and imaging technologies in specific sub-studies. The study design allows for additional visits if participants experience asthma exacerbations. Healthy volunteers and those with mild/moderate asthma only have a baseline visit. Throughout the study, participants undergo detailed clinical and biological evaluations including questionnaires, lung function tests, and biomarker sampling. The research team measures asthma control, lung function, frequency of exacerbations, and medication use over time. By tracking these outcomes and analyzing biological data, the study seeks to identify markers linked to treatment remission, response, or non-response. Safety and long-term effects are monitored during the three-year follow-up period.

Researchers are evaluating the effect of starting Airsupra inhaler treatment in emergency departments (ED) on reducing acute asthma recurrence and other related outcomes over three months. The study focuses on adults aged 18 to 54 who visit the ED for asthma exacerbations and are discharged with a short course of systemic corticosteroids. This trial is a cluster randomized, open-label study comparing Airsupra use to usual care across multiple centers. Participants will be assigned by site to either receive usual care or Airsupra as their rescue inhaler along with corticosteroids. Airsupra dosing is as needed, with up to six doses per day. The study will run for about four to five months of enrollment per site, with follow-up assessments conducted at approximately 3, 6, and 12 weeks after the ED discharge to monitor asthma control, relapse, and recurrence. During the study, patients will complete interviews and chart reviews in the ED, and follow-up will include telephone or text contact to assess their clinical status and medication use. Medical records from before and after enrollment will be reviewed to identify asthma exacerbations. The main outcome is asthma recurrence within three months, with asthma control and early relapse also measured. Participants’ data will be securely managed throughout the study period, which extends up to 12 weeks post-ED visit.

Researchers are observing the safety and effectiveness of Atectura inhalation capsule in people aged 12 to 100 years with asthma over a 24-week period. This non-interventional, open-label study takes place across multiple centers and follows routine clinical practice without additional diagnostic or monitoring procedures beyond standard care. The study aims to gather real-world data on the use of Atectura as prescribed under approved labeling in Korea. Participants will use one of three doses of Atectura inhalation capsule delivered via Breezhaler: 150/80 µg, 150/160 µg, or 150/320 µg of indacaterol acetate/mometasone furoate. Treatments are prescribed by physicians according to routine care, and patients who have already started Atectura before joining the study will be included. No randomization or placebo control is involved since this is an observational study. During the study, researchers will track adverse events and serious adverse events over 24 weeks to evaluate safety. Lung function changes will be measured by trough FEV1 at baseline and week 12, along with asthma control using the ACT score. Effectiveness will also be assessed by investigators at week 12. Patient data on drug reactions and lung function changes will be collected to better understand treatment impact. The study runs until December 2026 and involves regular clinical assessments without extra tests beyond standard asthma care.

Researchers are observing adult patients with asthma who have been prescribed Enerzair inhalation capsules to evaluate the safety and effectiveness of this treatment over a 24-week period in real-world clinical settings. This study is open-label, prospective, multicenter, and single-arm, designed to monitor outcomes without additional interventions beyond routine care. Participants will receive one of two doses of Enerzair via Breezhaler, either 150/50/80 micrograms or 150/50/160 micrograms, as prescribed according to approved labeling in Korea. No extra diagnostic or monitoring procedures beyond standard clinical practice will be conducted during the study. Throughout the study, participants will be monitored for adverse events and serious adverse events for up to 24 weeks. Researchers will also assess lung function using trough FEV1 measurements and asthma control using the ACT score at baseline and week 12. Effectiveness will be evaluated by investigator assessment, and patient characteristics related to safety and efficacy outcomes will be recorded. The study involves collection of data without altering prescribed treatment and ensures ongoing observation in a routine care environment.

Researchers are evaluating the effects of increasing soluble fiber intake on the gut microbiome in children aged 6 to 17 with asthma. This Phase II randomized controlled trial aims to understand how diet, specifically fiber intake, may influence asthma symptoms and related biological pathways. Participants will be assessed through dietary recalls and various biological samples to explore connections between diet and asthma control. Participants will be randomly assigned to receive either soluble fiber (Fruitafit Inulin) or a placebo (Maltodextrin). After initial assessments including dietary recall, nasal wash, blood samples, and an asthma control questionnaire, participants will receive counseling on how to include the study product in their diet. Over approximately 30 days, participants will collect and submit three stool samples for microbiome and metabolomic analysis, and repeat assessments at a second visit about 25 days later. Throughout the study, participants will complete questionnaires, provide biological samples including blood, nasal wash, and stool, and undergo dietary intake assessments. Researchers will monitor gut microbiome diversity, asthma control, nasal inflammation, and circulating short-chain fatty acids. The study includes safety monitoring for minimal risks such as discomfort from sample collection and blood draws. Participants receive compensation and partial dietary results, with total involvement lasting about one month.

This research focuses on chronic inflammatory lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, cystic fibrosis (CF), primary ciliary dyskinesia (PCD), and interstitial lung diseases (ILD). These conditions involve inflammation and changes in lung structure with a wide range of symptoms and features. The study aims to analyze various characteristics including clinical, biological, and microbiological traits, as well as respiratory exposures and mechanisms related to airway inflammation, to better understand these diseases beyond their initial diagnosis. The study is a prospective cohort conducted at the University Hospital of Reims, France, including adults aged 18 and older diagnosed with the listed respiratory diseases or healthy volunteers as controls. Participants will be followed over a 10-year period with data collected at inclusion and follow-up visits, while controls will only provide data at inclusion. No specific treatments are given as part of the study; care continues as usual. Throughout the study, information such as demographics, disease history, lung function tests, CT scans, and respiratory sample analyses will be collected and stored in an anonymous database. Researchers will use statistical and machine learning methods to identify patient groups with similar disease patterns and predict disease progression and treatment responses. The study is planned to start in September 2025 with a recruitment period lasting five years and follow-up for a decade thereafter.

Researchers are investigating frequent acute exacerbations in asthma, which are sudden worsening episodes that significantly impact health and healthcare resources. This study aims to identify characteristics and risk factors of patients with frequent exacerbations compared to those with fewer episodes, regardless of asthma severity. It also seeks to develop a predictive model and understand the prognosis and treatment responses of this subgroup, which may represent a distinct asthma type. This observational study involves two groups: asthma patients with frequent exacerbations and those without. There is no intervention or treatment applied as part of this research. Instead, it focuses on collecting detailed information about clinical features, inflammation markers, lung function, comorbidities, environmental exposures, and imaging findings over time to better understand these patterns. Participants will attend outpatient visits where researchers will assess their asthma symptoms, perform lung function tests and lung CT scans, and collect blood and sputum samples to measure inflammation markers. These assessments are done at baseline and followed up for one year to track acute exacerbations and other health changes. The main outcome measured is the frequency of acute asthma exacerbations, with additional evaluations of immune markers and lung health to support the study goals.

Asthma is a common condition marked by breathing difficulties, coughing, and wheezing. Diagnosing asthma relies on identifying airflow obstruction, airway sensitivity, and inflammation, but international guidelines vary in their criteria. This research evaluates how well these guidelines agree in diagnosing asthma and explores additional lung function tests like impulse oscillometry (IOS), which is not commonly included in guidelines but available at the Portsmouth lung function service. The study involves analyzing routine lung function data from patients attending the severe asthma service at Queen Alexandra Hospital in Portsmouth. It compares standard diagnostic tests recommended by international guidelines with IOS, a simple, non-invasive test measuring lung function. The goal is to see if IOS can improve the accuracy and ease of diagnosing asthma in adults. Participants' lung function data will be reviewed using both guideline-based and additional criteria, focusing on how well each method identifies asthma. Outcomes include scores based on international asthma guidelines and numbers related to non-guideline lung function tests, assessed about four weeks after recruitment. The study uses an opt-out consent process and aims to provide insights that may enhance asthma diagnosis and management.

Researchers are evaluating the efficacy and safety of benralizumab, given as a subcutaneous injection, in children aged 6 to under 18 years who have severe eosinophilic asthma. This study focuses on patients with a history of asthma attacks and uncontrolled symptoms despite using high-dose inhaled corticosteroids and at least one additional asthma controller medication. The study is a Phase III, randomized, double-blind, placebo-controlled trial designed to measure the time to first asthma exacerbation. The study includes a screening period lasting between 4 to 12 weeks to determine eligibility. Participants are randomly assigned to receive either benralizumab or a placebo injection during the double-blind treatment period, which lasts at least 16 weeks or until an asthma exacerbation occurs. Those who experience an exacerbation during this period may continue treatment in an open-label extension phase lasting at least 48 weeks, followed by an end-of-treatment visit 8 weeks after the last dose. During the study, participants will have regular visits for assessments including asthma control questionnaires, symptom scoring, lung function tests, and blood tests for benralizumab levels and antibodies. Researchers will monitor asthma exacerbations, medication use, night-time awakenings, and quality of life measures. Safety and treatment adherence will be closely observed throughout the study and the extension period, with total participation lasting over a year depending on individual progress.